Press release
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the launch of a new preclinical development targeting a strong anti microbial resistant bacteria, Klebsiella pneumonia.
- Klebsiella pneumoniae is responsible for severe infections and stands out for its high resistance to antibiotics
- PHAXIAM’s anti-Klebsiella pneumoniae phages to enter pre-clinical development to assess their efficacy in lung, blood and urinary tract infections, in addition to the three major targets already developed (S. aureus, P. aeruginosa, E. coli)